Dr. Lametra Scott

The FDA has approved a gene therapy for sickle cell disease in children as young as 2 years old, expanding access previously limited to those 12 and older. The treatment involves gene-editing a patient's stem cells to produce fetal hemoglobin, offering a potential cure without requiring a donor match.